Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Biogen's Next Quarterly Earnings Report

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Valued at a market cap of $26.2 billion, the company is scheduled to announce its fiscal Q4 earnings for 2025 in the near future. 

Ahead of this event, analysts expect this healthcare company to report a profit of $1.72 per share, down 50% from $3.44 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion. In Q3, its EPS of $4.81 exceeded the consensus estimates by a notable margin of 23.7%. 

Fundamentals

See More
  • Market Capitalization, $K 26,156,968
  • Shares Outstanding, K 146,702
  • Annual Sales, $ 9,676 M
  • Annual Income, $ 1,632 M
  • EBIT $ 2,735 M
  • EBITDA $ 3,698 M
  • 60-Month Beta 0.13
  • Price/Sales 2.60
  • Price/Cash Flow 8.03
  • Price/Book 1.50

Options Overview Details

View History
  • Implied Volatility 33.94% (-1.30%)
  • Historical Volatility 29.60%
  • IV Percentile 37%
  • IV Rank 17.13%
  • IV High 64.86% on 04/09/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 2) 3.75 (2.19%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 3,847
  • Volume Avg (30-Day) 2,489
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 72,970
  • Open Int (30-Day) 72,601
  • Expected Range 167.13 to 174.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.72
  • Number of Estimates 26
  • High Estimate 3.54
  • Low Estimate 1.30
  • Prior Year 3.44
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.60 +3.00%
on 01/14/26
190.20 -10.32%
on 01/09/26
-3.53 (-2.02%)
since 12/12/25
3-Month
138.00 +23.61%
on 10/30/25
190.20 -10.32%
on 01/09/26
+25.26 (+17.39%)
since 10/14/25
52-Week
110.04 +55.01%
on 04/09/25
190.20 -10.32%
on 01/09/26
+27.51 (+19.23%)
since 01/14/25

Most Recent Stories

More News
What to Expect From Biogen's Next Quarterly Earnings Report

Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.

XLV : 157.03 (+0.19%)
$SPX : 6,894.17 (-1.00%)
BIIB : 170.96 (-4.12%)
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 Biogen...

IONS : 78.70 (-0.98%)
BIIB : 170.96 (-4.12%)
3 Reasons to Sell BIIB and 1 Stock to Buy Instead

3 Reasons to Sell BIIB and 1 Stock to Buy Instead

BIIB : 170.96 (-4.12%)
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in first half 2027— ...

STOK : 30.44 (-0.46%)
BIIB : 170.96 (-4.12%)
Stocks Finish Higher on Strength in Chip Makers and Energy Producers

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.77%. March E-mini S&P...

MSTR : 179.00 (+3.47%)
MPC : 182.07 (+3.54%)
HL : 23.88 (-1.77%)
CDE : 20.70 (-1.24%)
ADI : 294.63 (-0.53%)
GLXY : 27.49 (+2.50%)
JNJ : 217.11 (+1.62%)
SLB : 47.11 (+2.64%)
QXO : 24.81 (-1.39%)
AMGN : 325.83 (+0.47%)
COIN : 255.70 (+1.19%)
PNR : 103.39 (+0.15%)
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1 -ALS Over 3 years, a subset of QALSODY-treated participants...

BIIB : 170.96 (-4.12%)
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

BIIB : 170.96 (-4.12%)
Biogen (BIIB) Stock Trades Up, Here Is Why

Biogen (BIIB) Stock Trades Up, Here Is Why

BIIB : 170.96 (-4.12%)
1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds

1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds

KDP : 28.11 (+1.41%)
DASH : 210.25 (-3.29%)
BIIB : 170.96 (-4.12%)
MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too?

MSTR was being eyed for possible Nasdaq-100 removal, but when the index reconstitutes next week, it will get to stay. Other companies, including Biogen and Lululemon, will be removed.

MSTR : 179.00 (+3.47%)
LULU : 204.41 (-3.53%)
^BTCUSD : 96,972.80 (+3.10%)
BIIB : 170.96 (-4.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 193.33
2nd Resistance Point 189.82
1st Resistance Point 184.06
Last Price 170.96
1st Support Level 174.79
2nd Support Level 171.29
3rd Support Level 165.53

See More

52-Week High 190.20
Last Price 170.96
Fibonacci 61.8% 159.58
Fibonacci 50% 150.12
Fibonacci 38.2% 140.66
52-Week Low 110.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar